

GNMX

Corgi Genomics & Precision Medicine ETF

Fund Description

GNMX seeks capital appreciation through a portfolio of companies tied to the genomics and precision medicine value chain, from sequencing platforms and bioinformatics engines to gene editors, molecular diagnostics, targeted therapies, and clinical data platforms.

FactSet Analyst Report

GNMX targets pure-play or the top 10 companies materially involved in genomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies. The fund considers companies deriving significant revenue from this theme, spanning those that support personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development. Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Other factors include supply chain positioning, growth potential, and valuation. Up to 15% may be allocated to illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.

